Moderna (MRNA) Stock Price Today—Real Time Charts and Quotes

Q: What's the stock price of Moderna (MRNA) today?

Moderna (MRNA) is currently trading at $45.15, with a 24h change of -2.5%. The 52-week trading range is $22.28–$59.55.

Q: What are the 52-week high and low prices for Moderna (MRNA)?

MRNA has a 52-week high of $59.55 and a 52-week low of $22.28, with the current price at $45.15.

Q: What is the price-to-earnings (P/E) ratio of Moderna (MRNA)? What does it indicate?

The current P/E ratio (TTM) of MRNA is -4.065063784549964, indicating how much investors pay for each dollar of earnings. A higher P/E ratio often reflects stronger growth expectations, while a lower P/E ratio may suggest a more attractive valuation or slower growth. Comparing it with the average P/E of the Biotechnology industry for a better context.

Q: What is the market cap of Moderna (MRNA)?

Moderna (MRNA) currently has a market cap of approximately $17.99B.

Q: What is the most recent quarterly earnings per share (EPS) for Moderna (MRNA)?

Moderna (MRNA)'s diluted earnings per share (Diluted EPS) is -8.086075949367089. EPS = Net Income / Total Diluted Shares, which is a key metric for measuring a company's profitability.

Q: Should you buy or sell Moderna (MRNA) now?

As of now, MRNA is trading at $45.15, with a P/E ratio of -4.065063784549964 and a diluted EPS of -8.086075949367089. Your buy or sell decisions should be based on your investment goals and risk tolerance. We recommend making an overall judgment by considering Moderna's financial reports, the outlook of the Biotechnology sector, and your own holdings. Investing involves risk—please make decisions prudently.

Q: What factors can affect the stock price of Moderna (MRNA)?

Key factors include: company quarterly reports (revenue, EPS), competition and trends in the Biotechnology sector, macroeconomic environment (interest rate, inflation), market sentiment, as well as major events like product releases and mergers & acquisitions.

Q: How to buy Moderna (MRNA) stock?

You can buy Moderna (MRNA) through Gate. Sign up for a Gate account and complete identity verification, then go to the Moderna trading page to make a purchase. Gate supports fractional share trading, so you can start investing without buying a whole share.

$45,15

-$1,16(-2,50%)

*Data last updated: 2026-05-04 03:39 (UTC+8)

As of 2026-05-04 03:39, Moderna (MRNA) is priced at $45,15, with a total market cap of $17,99B, a P/E ratio of -4,06, and a dividend yield of 0,00%. Today, the stock price fluctuated between $43,67 and $51,44. The current price is 3,38% above the day's low and 12,22% below the day's high, with a trading volume of 10,23M. Over the past 52 weeks, MRNA has traded between $22,28 to $59,55, and the current price is -24,18% away from the 52-week high.

MRNA Key Stats

Yesterday's Close$45,94

Market Cap$17,99B

Volume10,23M

P/E Ratio-4,06

Dividend Yield (TTM)0,00%

Diluted EPS (TTM)8,09

Net Income (FY)-$2,82B

Revenue (FY)$1,94B

Earnings Date2026-07-31

EPS Estimate2,12

Revenue Estimate$103,25M

Shares Outstanding391,66M

Beta (1Y)1.336

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

SectorHealthcare

IndustryBiotechnology

CEOStéphane Bancel

HeadquartersCambridge,MA,US

Official Websitehttps://www.modernatx.com

Employees (FY)4,70K

Average Revenue (1Y)$413,61K

Net Income per Employee-$600,42K

Moderna (MRNA) FAQ

What's the stock price of Moderna (MRNA) today?

Moderna (MRNA) is currently trading at $45,15, with a 24h change of -2,50%. The 52-week trading range is $22,28–$59,55.

What are the 52-week high and low prices for Moderna (MRNA)?

What is the price-to-earnings (P/E) ratio of Moderna (MRNA)? What does it indicate?

What is the market cap of Moderna (MRNA)?

What is the most recent quarterly earnings per share (EPS) for Moderna (MRNA)?

Should you buy or sell Moderna (MRNA) now?

What factors can affect the stock price of Moderna (MRNA)?

How to buy Moderna (MRNA) stock?

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

MRNA

CFD

Fai trading

Moderna (MRNA) Latest News

2026-03-27 05:31

澳企业家公开AI设计宠物mRNA癌症疫苗流程，涉及300GB基因数据与多模型协作

Gate News消息，3月27日，澳大利亚AI咨询公司创始人Paul Conyngham在X平台披露其借助多款AI聊天机器人为宠物犬设计个性化mRNA癌症疫苗的完整技术流程。该犬于2024年5月被诊断为恶性肥大细胞癌，随后通过全基因组与RNA测序获取约300GB数据，并在ChatGPT、Gemini及Grok分工协作下完成靶点筛选、蛋白结构建模及疫苗序列设计，最终锁定c-KIT基因突变并筛选出7个新抗原靶点。疫苗由新南威尔士大学相关研究团队制备，并在昆士兰大学兽医学院实施接种。整体治疗方案包括mRNA疫苗、酪氨酸激酶抑制剂及PD-1抑制剂的联合应用，其给药时序由AI辅助规划。2025年12月开始治疗后，三个月内部分肿瘤出现缩小，但仍有未响应病灶需通过手术处理。专家指出，该案例属于单一个体实践，尚不构成普适性医学结论。

2026-03-16 07:15

工程师用 AI 设计 mRNA 疫苗治疗救助犬癌症，肿瘤缩小一半但未治愈，监管审批成最大障碍

Gate News 消息，3 月 16 日，悉尼机器学习工程师 Paul Conyngham 使用 ChatGPT 和 DeepMind 的 AlphaFold 自学 mRNA 疫苗设计，为患肥大细胞癌的救助犬 Rosie 打造了定制疫苗。他与新南威尔士大学（UNSW）RNA 研究所合作完成疫苗设计，并在昆士兰大学 Gatton 兽医学院完成注射。注射后，Rosie 的一个肿瘤明显缩小，治疗兽医 Paola Allavena 教授称「肿瘤大概缩小了一半」。该故事近日在社交媒体上被广泛传播为「AI 治愈了狗的癌症」。但据新南威尔士大学发表的原始报道，Rosie 的癌症目前仍在进展，距离治愈仍有距离。生物医学工程师 Patrick Heizer 指出，制造单个 mRNA 疫苗在技术上「极其简单」，真正困难且昂贵的是在随机对照试验中证明疫苗同时安全且有效，而这一步尚未完成。 Conyngham 本人指出，整个过程中最大的障碍并非疫苗设计，而是伦理审批：他花了三个月、每晚两小时来撰写一份 100 页的伦理审批文件，「比制造疫苗更难」。生物学作者 Ruxandra Teslo 在分析中引用了 GitLab 联合创始人 Sid Sijbrandij 的类似经历（骨肉瘤复发后自费探索实验疗法，2025 年起未再复发），认为早期临床试验的监管官僚是阻碍个性化医疗落地的核心瓶颈。

2026-03-09 09:00